Radiotherapy in epithelial ovarian cancer: State of the art

FORUM - Trends in Experimental and Clinical Medicine

Volumn 10, Issue 4, 2000, Pages 335-352

  Cardenes, H ^a   Randall, M E ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

Consolidative radiotherapy; Intraperitoneal 32P; Ovarian cancer; Whole abdomen irradiation

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CHROMIUM PHOSPHATE P 32; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; EPITHELIUM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PROGNOSIS; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE;

CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RESEARCH DESIGN; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0034436089     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Cancer Statistics, 1998
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results of two prospective randomized trials
4. Radioactive chromic phosphate suspension: Studies on distribution, dose absorption, and effective therapeutic radiation in phantoms, dogs and patients
5. 32P colloids
6. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA, high risk) ovarian cancer. GOG #95
7. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradiation as adjuvant treatment of ovarian cancer
8. Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further therapy or chromic phosphate
9. Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate
10. Intraperitoneal radioactive Phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy
11. 32P chromic phosphate therapy of the peritoneum using SPECT
12. Postoperative treatment of early cancer of the ovary: A random trial between postoperative irradiation and chemotherapy
13. Prognostic factors in patients with Stage I epithelial ovarian cancer
14. Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and WAR
15. Choice of postoperative therapy based on prognostic factors
16. Abdominopelvic radiotherapy in ovarian cancer: A 10-year experience
17. Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a complete pelvic operation
18. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: A 15 years review
19. Randomized study of whole abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer
20. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy
21. The role of adjuvant therapy in stage I ovarian cancer
22. Treatment of carcinoma of the ovary: Operation, irradiation and chemotherapy
23. Ovarian cancer: Screening, treatment and follow-up
24. Radiotherapeutic management of ovarian cancer
25. Postoperative abdomino-pelvic radiation therapy for ovarian cancer
26. Determinants of survival of patients with epithelial ovarian carcinoma following whole abdominal irradiation (WAR)
27. Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma
28. Analysis of prognostic factors in stage I epithelial ovarian cancer. Importance of the degree of differentiation and DNA ploidy in predicting relapse
29. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy
30. The multimodal approach to the treatment of stage III ovarian carcinoma
31. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer
32. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second-look
33. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer
34. Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in "high risk" epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)
35. Primary treatment of stage III ovarian carcinoma with sequential chemotherapy and whole abdominal radiation therapy
36. Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: Results of a prospective treatment protocol
37. Chemotherapy, early surgical reassessment and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: Results of a Gynecologic Oncology Group study
38. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer
39. Integrating radiation therapy into the management of ovarian cancer
40. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer?
41. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma
42. Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer
43. Role of an early second-look laparotomy in ovarian cancer
44. Correlation between response to cisplatinum combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck
45. Radiation survival parameters of anti-neoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoxime
46. Collateral resistance to photon and neutron irradiation is associated with acquired cisplatin resistance in human ovarian tumour cells
47. Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line
48. X-Ray and cis-diammine dichoroplatinum cross-resistance in human tumour cell lines
49. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma
50. Salvage whole abdomen radiation therapy: Its role in ovarian cancer
51. Salvage whole abdominal radiation therapy for ovarian cancer: A twelve year experience
52. Stage III ovarian carcinoma: An analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage
53. Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer
54. Efficacy of radiation therapy for chemo-resistant ovarian cancers
55. Whole-abdomen radiation therapy as salvage treatment for epithelial ovarian carcinoma
56. 32P) as salvage therapy for persistent carcinoma of the ovary after surgical restaging
57. 32P in stage III epithelial carcinoma of the ovary
58. 32P following negative second-look laparotomy for epithelial ovarian cancer
59. Phosphorous-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy
60. Intraperitoneal radioimmunotherapy of ovarian cancer with 177-Lu-CC49: A phase I/II study
61. Post-operative radiation therapy for epithelial ovarian cancer: The curative role based on 24-year experience
62. A randomized clinical trial of moving strip versus open field whole abdominal irradiation in patients with invasive epithelial cancer of the ovary
63. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II and III ovarian cancer
64. A standard dose of radiation for "microscopic disease" is not appropriate
65. Radiation dose response for subclinical metastases
66. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma
67. Effect of filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma
68. Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma
69. Risk of second tumours in a cohort of patients with ovarian carcinoma
70. Risk of leukemia after platinum-based chemotherapy for ovarian cancer
71. Neoadjuvant chemotherapy for advanced ovarian cancer
72. Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. A pilot study
73. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: A Gynecological Oncology Group pilot study
74. Use of concomitant low dose cisplatinum and whole abdominal radiation (WARP) as salvage therapy for persistent ovarian carcinoma after positive second look procedure: A pilot study
75. Taxol as a randiosensitizer: A flow cytometric study